在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

GAA Recombinant Monoclonal Antibody

  • 中文名稱:
    GAA重組抗體
  • 貨號:
    CSB-RA566370A0HU
  • 規(guī)格:
    ¥1320
  • 圖片:
    • IHC image of CSB-RA566370A0HU diluted at 1:50 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.15% DAB.
    • IHC image of CSB-RA566370A0HU diluted at 1:50 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.15% DAB.
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品描述:
    CSB-RA566370A0HU GAA重組單克隆抗體是針對酸性α-葡萄糖苷酶(GAA)靶點開發(fā)的高特異性科研工具,適用于酶聯(lián)免疫吸附(ELISA)和免疫組織化學(xué)(IHC)實驗。該抗體識別的GAA蛋白是溶酶體糖原代謝的關(guān)鍵酶,其功能異常與糖原貯積病II型(龐貝病)等遺傳代謝疾病密切相關(guān)。經(jīng)實驗驗證,本產(chǎn)品在IHC應(yīng)用中展現(xiàn)優(yōu)異的組織抗原定位能力,推薦使用稀釋比例為1:50至1:200,可清晰檢測石蠟包埋樣本中GAA的細胞特異性表達分布。其在ELISA平臺的應(yīng)用則支持靶蛋白的定量分析需求,為研究人員提供可靠的檢測數(shù)據(jù)。該抗體適用于疾病模型構(gòu)建、代謝通路研究及治療性酶活性調(diào)控等基礎(chǔ)科研領(lǐng)域,特別在糖原代謝異常相關(guān)疾病的病理機制探索、基因治療靶點驗證等方向具有應(yīng)用價值。通過嚴格的免疫原篩選和表位驗證,確保抗體與GAA蛋白的高度結(jié)合特異性,為體外實驗提供精準的檢測保障。
  • Uniprot No.:
  • 基因名:
  • 別名:
    Lysosomal alpha-glucosidase (EC 3.2.1.20) (Acid maltase) (Aglucosidase alfa) [Cleaved into: 76 kDa lysosomal alpha-glucosidase, 70 kDa lysosomal alpha-glucosidase], GAA
  • 反應(yīng)種屬:
    Human
  • 免疫原:
    A synthesized peptide derived from Human GAA
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 抗體亞型:
    Rabbit IgG
  • 純化方式:
    Affinity-chromatography
  • 克隆號:
    5E5
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
  • 產(chǎn)品提供形式:
    Liquid
  • 應(yīng)用范圍:
    ELISA, IHC
  • 推薦稀釋比:
    Application Recommended Dilution
    IHC 1:50-1:200
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

  • 功能:
    Essential for the degradation of glycogen in lysosomes. Has highest activity on alpha-1,4-linked glycosidic linkages, but can also hydrolyze alpha-1,6-linked glucans.
  • 基因功能參考文獻:
    1. PI-rhGAA may have the potential to be a useful therapeutic option for improving the treatment of Pompe disease. PMID: 29102549
    2. The most common mutation was c.-32-13T, G. in Pompe disease. PMID: 29181627
    3. The narrow substrate-binding pocket of rhGAA is located near the C-terminal ends of beta-strands of the catalytic (beta/alpha)8 domain and shaped by a loop from the N-terminal beta-sheet domain and both inserts I and II. PMID: 29061980
    4. This is the first study of rhGAA to differentiate M6P glycans and identify their attachment sites, despite rhGAA already being an approved drug for Pompe disease. PMID: 29274340
    5. GAA mutation is associated with Pompe disease. PMID: 28763149
    6. Enzyme activities (acid alpha-glucosidase (GAA), galactocerebrosidase (GALC), glucocerebrosidase (GBA), alpha-galactosidase A (GLA), alpha-iduronidase (IDUA) and sphingomyeline phosphodiesterase-1 (SMPD-1)) were measured on ~43,000 de-identified dried blood spot (DBS) punches, and screen positive samples were submitted for DNA sequencing to obtain genotype confirmation of disease risk PMID: 27238910
    7. enzyme replacement therapy (ERT) (alglucosidase alfa) stabilizes respiratory function and improves mobility and muscle strength in late-onset Pompe disease.Lysosomal glycogen in muscle biopsies from treatment-naive LOPD patients was reduced post-ERT (alglucosidase alfa). PMID: 27473031
    8. In adults with Pompe disease, antibody formation does not interfere with rhGAA efficacy in the majority of patients, is associated with IARs, and may be attenuated by the IVS1/delex18 GAA genotype PMID: 27362911
    9. Reanalysis of the patient's DNA sample using next generation sequencing (NGS) of a panel of target genes causing glycogen storage disorders demonstrated compound heterozygosity for a point mutation and an exonic deletion in the GAA gene. PMID: 28657663
    10. Thirteen novel and two common GAA mutations were identified in this study. The allelic frequency of c.2662G > T (p.Glu888X) was 23.1% in northern Chinese patients and 4.2% in southern Chinese patients, whereas the allelic frequency of c.1935C >A (p.Asp645Glu) was 20.8% in southern and 3.8% in northern Chinese patients. PMID: 28394184
    11. This is the first report of the alpha-glucosidase inhibitory activity of compounds 20, 26, and 29, and the findings support the important role of Eremanthus species as novel sources of new drugs and/or herbal remedies for treatment of type 2 diabetes. PMID: 27322221
    12. Compared with controls, GAA gene expression levels in coronary artery disease (CAD) patients were significantly increased, suggesting that GAA may be involved in the CAD development. PMID: 26580301
    13. Study reports on the clinical, biochemical, morphological, muscle imaging, and genetic findings of six adult Pompe patients from five unrelated families with the c.-32-13T>G GAA gene mutation in homozygous state. All patients had decreased GAA activity and elevated creatine kinase levels. PMID: 26231297
    14. glycogen storage disease type II is caused by deficiency of GAA activity resulting from mutation of GAA gene PMID: 26575883
    15. RT-PCR followed by DNA sequence analysis of patients with Pompe disease revealed new variant in GAA gene resulting in aberrant splicing event. PMID: 25243733
    16. Findings indicate that GAA c.2238G > C (p.W746C) novel mutation is the most common mutation in mainland Chinese late-onset Pompe patients, as observed in Taiwanese patients expanding the genetic spectrum of the disease. PMID: 25526786
    17. this study shows several alterations distributed along the GAA gene in a sample of Brazilian families. PMID: 25681614
    18. Mutations in acid alpha-glucosidase gene is associated with Pompe disease. PMID: 25026126
    19. GAA deficiency results in reduced mTORC1 activation that is partly responsible for the skeletal muscle wasting phenotype and can be amerliorated by leucine supplementation. PMID: 25231351
    20. The phenotype LO-GSDII with GAA mutation in the North of Italy seems not significantly different from other LO-GSDII populations in Europe or the USA. PMID: 24158270
    21. Data shows the largest informative family with late-onset Pompe disease described in the literature showing a peculiar complex set of mutations of GAA gene that may partially elucidate the clinical heterogeneity of this family. PMID: 24107549
    22. 7 of 27 in: Gene. 2014 Mar 1;537(1) Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease. PMID: 24384324
    23. This study demonstrates that the c.-32-13T>G mutation of GAA gene abrogates the binding of the splicing factor U2AF65 to the polypyrimidine tract of exon 2 and that several splicing factors affect exon 2 inclusion. PMID: 24150945
    24. study describes two unrelated cases affected with classical early-onset Pompe disease, both pertaining to the same small Mexican region, with the same novel homozygous frameshift mutation at gene GAA (c.1987delC) PMID: 24399866
    25. Mutations in the GAA gene is associated with glycogen storage disease type II. PMID: 23884227
    26. Adult patients with alpha-glucosidase mutations other than c.-32-13 T>G can have very low alpha-glucosidase activity in fibroblasts but express higher activity in muscle and store less glycogen in muscle than patients with infantile Pompe disease. PMID: 23000108
    27. Study gave an update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. PMID: 22644586
    28. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients PMID: 22658377
    29. Report genetic testing to indentify GAA mutations in German patients with late-onset glycogen storage disease type II. PMID: 18607768
    30. we define a critical role for endoplasmic reticulum stress in the activation of autophagy due to the 546G>T acid alpha glucosidase mutation PMID: 21982629
    31. No common mutation is found in association with low levels of acid alpha-glucosidase activity in late-onset Pompe disease; most patients produce unprocessed forms of GAA protein compared with patients who have higher GAA activity. PMID: 21484825
    32. Mutation analysis of the GAA gene revealed the p.D645E in all patients with Pompe disease, suggesting it as the most common mutation in the Thai population. PMID: 21039225
    33. The enzymatic screening of Pompe disease can be justified in patients with myopathies of unknown etiology in this report of a Mexican patient with late-onset glycogen-storage disease type 2. PMID: 20350966
    34. Data show that p.R1147G missense mutation impaired glucosidase activity. PMID: 19834502
    35. Homozygosity for multiple contiguous single-nucleotide polymorphisms as an indicator of large heterozygous deletions: identification of a novel heterozygous 8-kb intragenic deletion (IVS7-19 to IVS15-17) in a patient with glycogen storage disease type II PMID: 11854868
    36. novel target of the Notch-1/Hes-1 signaling pathway PMID: 12065598
    37. 2 novel mutations of the acid alpha-glucosidase gene, P361L and R437C, were found in a juvenile-onset glycogen storage disease type II (GSDII) 16-year-old Chinese patient. The asymptomatic 13-year-old brother of the proband is also compound heterozygote PMID: 12601120
    38. mutations in the alpha glucosidase gene is associated with infantile onset glycogen storage disease type II. PMID: 12923862
    39. Childhood Pompe disease demonstrating phenotypic variability of p.Asp645Asn. PMID: 15145338
    40. data show that the mature forms of GAA characterized by polypeptides of 76 or 70 kDa are in fact larger molecular mass multicomponent enzyme complexes; peptides released during proteolytic processing remained tightly associated with the major species PMID: 15520017
    41. 2 novel mutations (Ala237Val and Gly293Arg) were foundin the acid alpha-glucosidase gene in a Pompe disease patient with vascular involvement. PMID: 15668445
    42. Acid-alpha-glucosidase activity and specific activity, and lysosomal glycogen content are useful predictors of age of onset in Pompe disease PMID: 15993875
    43. Complete molecular analysis of the GAA gene of patients with late onset glycogen storage disease type II shows missense mutations and splicing mutations. PMID: 16917947
    44. From 14 Argentinean patients diagnosed with either infantile or late-onset disease, we identified 14 distinct mutations in the acid alpha-glucosidase (GAA) gene including nine novel variants. PMID: 17056254
    45. Two new missense mutations (p.266Pro>Ser and p.439Met>Lys) were new missense mutations causing late onset GSD II. PMID: 17092519
    46. Patients with the same c.-32-13T-->G haplotype (c.q. GAA genotype) may manifest first symptoms at different ages, indicating that secondary factors may substantially influence the clinical course of patients with this mutation. PMID: 17210890
    47. demonstrated a significant increase of GAA activity (1.3-7.5-fold) after imino sugar treatment in fibroblasts from patients carrying the mutations L552P (three patients) and G549R (one patient) PMID: 17213836
    48. N-glycans of recombinant human GAA were expressed in the milk of transgenic rabbits. PMID: 17293352
    49. The role of autophagy in Pompe disease was examined by analyzing single muscle fibers. PMID: 17592248
    50. Mutations in glucosidase alpha is asspciated with glycogen storage disease type II PMID: 17616415

    顯示更多

    收起更多

  • 相關(guān)疾病:
    Glycogen storage disease 2 (GSD2)
  • 亞細胞定位:
    Lysosome. Lysosome membrane.
  • 蛋白家族:
    Glycosyl hydrolase 31 family
  • 數(shù)據(jù)庫鏈接:

    HGNC: 4065

    OMIM: 232300

    KEGG: hsa:2548

    STRING: 9606.ENSP00000305692

    UniGene: Hs.1437



主站蜘蛛池模板: 久久www免费人成_看片中文| 又色又爽又黄的视频软件app| 精品国产一区二区三区av性色| 国产精品国产三级国产av剧情| 久久99久久99精品中文字幕| 国产精品视频一区二区亚瑟| 久久国产乱子伦精品免费女人| 波多野结衣av高清一区二区三区| 亚洲人成色77777在线观看大战p| 中文字幕人妻色偷偷久久| 少女韩国电视剧在线观看完整| 亚洲精品一区国产| 日日摸日日碰夜夜爽免费| 区二区三区国产精华液区别大吗| 被黑人猛躁10次高潮视频| 18禁在线永久免费观看| 国产真实夫妇交换视频| 亚洲一区二区三区在线观看网站| 国产成人精品a∨一区二区| 久久久久久夜精品精品免费啦| 国产日产韩国精品视频| 人人妻人人狠人人爽| 色欲αv一区二区三区天美传媒 | 国产精品国产三级在线...| 人妻熟女一区二区三区app下载| 久久精品国产99国产精品澳门| 香蕉免费一区二区三区在| 国产成人无码免费视频麻豆| 亚洲自偷自拍另类小说| 无码成a毛片免费| 无码一区二区波多野结衣播放搜索 | 2019亚洲午夜无码天堂| 亚洲精品色情app在线下载观看| 欧美乱妇高清无乱码| 人与禽交av在线播放| 免费啪视频在线观看视频日本| 日韩人妻中文无码一区二区三区| 色情无码www视频无码区小黄鸭| 国产亚洲视频在线观看播放| 欧美特级婬片毛多的少妇| 国产乱人伦精品一区二区在线观看|